Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study

被引：0
|
作者：
Cook, S.
Vermersch, P.
Comi, G.
Giovannoni, G.
Rammohan, K.
Rieckmann, P.
Sorensen, P. S.
Chang, P.
Hamlett, A.
Musch, B.
Viglietta, V.
Greenberg, S.
机构：
[1] Univ Med & Dent, Newark, NJ USA
[2] Univ Lille, Lille, France
[3] Univ Vita Salute, Milan, Italy
[4] Barts & London Queen Marys Sch Med & Dent, London, England
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Merck Serono SA, Geneva, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S20 / S20
页数：1
相关论文
共 50 条
  • [1] Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S137
  • [2] Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Rammohan, K.
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Verjee, R.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S249
  • [3] Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S136 - S136
  • [4] Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Verjee, R.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S249
  • [5] Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Sorensen, P. S.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Viglietta, V.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S137 - S137
  • [6] Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S206 - S206
  • [7] Safety of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, phase III, double-blind, placebo-controlled trial
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S128 - S128
  • [8] Efficacy of short-course oral therapy with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study
    Rieckmann, P.
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Sorensen, P.
    Vermersch, P.
    Chang, P.
    Greenberg, S. J.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (10) : 1283 - 1283
  • [9] Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study
    Vermersch, Patrick
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Kurukulasuriya, Nuwan C.
    Viglietta, Vissia
    Chang, Peter
    Papasouliotis, Orestis
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A246 - A247
  • [10] Relapses and lymphocyte counts before and after rescue therapy in the phase III, 96-week, double-blind, placebo-controlled CLARITY study of cladribine tablets for relapsing-remitting multiple sclerosis
    Sorensen, P. Soelberg
    Giovannoni, G.
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Vermersch, P.
    Kurukulasuriya, N.
    Hamlett, A.
    Galazka, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S411 - S411
12345